TickerFacts.

Company research / CORT

Corcept Therapeutics Inc (CORT)

Build a valuation ↗↓ Download CSV

SEC name CORCEPT THERAPEUTICS INC · CIK 0001088856 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Corcept Therapeutics Inc reported revenue of $761.41M. Revenue grew 12.8% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $830.81M.

Key ratios (year ended 2025-12-31)

5.9%
Operating margin
13.1%
Net margin
15.4%
Return on year-end equity
12.8%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-16

Headquarters locality: Menlo Park · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$830.81M$761.41M$675.04M$482.38M$401.86M$365.98M$353.87M$306.49M$251.25M$159.20M$81.32M
Cost of Revenue$14.09M$12.98M$10.88M$6.48M$5.38M$5.28M$5.58M$5.50M$5.21M$3.55M$2.06M
R&D Expense$253.86M$254.91M$246.89M$184.35M$130.99M$113.86M$114.76M$89.02M$75.25M$40.38M$23.84M
Operating Income$6.41M$44.80M$136.95M$107.28M$112.63M$124.48M$128.20M$111.61M$89.50M$52.85M$10.18M
Depreciation & Amortizationn/a$1.15M$795.0K$1.04M$1.26M$1.07M$525.0K$703.0K$236.0K$106.0K$87.0K
EBITDAn/a$45.95M$137.75M$108.32M$113.89M$125.55M$128.73M$112.31M$89.73M$52.96M$10.27M
Net Income$55.18M$99.65M$141.21M$106.14M$101.42M$112.51M$106.01M$94.18M$75.41M$129.12M$8.14M
EPS (Diluted)n/a$0.82$1.23$0.94$0.87$0.89$0.85$0.77$0.60$1.04$0.07
Total Assets$888.70M$836.65M$840.55M$621.52M$583.43M$423.76M$571.73M$412.31M$311.69M$220.54M$68.75M
Total Liabilities$182.93M$188.85M$160.96M$114.81M$81.59M$47.95M$48.39M$41.13M$35.81M$29.57Mn/a
Shareholders' Equity$705.78M$647.80M$679.59M$506.70M$501.84M$375.81M$523.34M$371.18M$275.88M$190.97M$41.38M
Cash & Equivalents$111.04M$120.50M$127.67M$135.55M$66.33M$77.62M$76.19M$31.27M$41.62M$31.06M$51.54M
Operating Cash Flow$109.70M$142.00M$198.29M$126.68M$120.32M$167.89M$151.97M$136.12M$115.67M$60.94M$18.39M
Capital Expenditures$2.78M$211.0K$2.17M$139.0K$413.0K$469.0K$1.24M$1.09M$298.0K$419.0K$194.0K
Free Cash Flow$106.92M$141.78M$196.12M$126.54M$119.91M$167.42M$150.73M$135.03M$115.37M$60.52M$18.20M
Share Repurchases$42.46M$172.91M$15.66M$0$0n/a$9.95M$30.98M$23.66M$0$0
Shares Outstandingn/a105.97M105.11M103.41M107.83M105.94M116.73M114.55M115.03M114.72M112.71M
Weighted Average Diluted Sharesn/a119.99M113.48M111.74M115.97M125.96M124.19M122.57M126.69M124.52M116.14M
EPS (Basic)n/a$0.95$1.35$1.02$0.95$0.97$0.92$0.82$0.65$1.14$0.07

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView